RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077
Landovitz, R. J., Zangeneh, S. Z., Chau, G., Grinsztejn, B., Eron, J. J., Dawood, H., Magnus, M., Liu, A. Y., Panchia, R., Hosseinipour, M. C., Kofron, R., Margolis, D. A., Rinehart, A., Adeyeye, A., Burns, D., McCauley, M., Cohen, M. S., & Currier, J. S. (2020). Cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077. Clinical Infectious Diseases, 70(2), 319-322. https://doi.org/10.1093/cid/ciz439
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
